Research Article

Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China

Table 1

Baseline information for participants.

CharacteristicsTotal (N = 91)Han population (N = 67)Tibetan population (N = 24) value

Age, years#65.36 ± 12.4465.99 ± 12.2563.63 ± 13.060.428
Height (m)#1.68 ± 0.081.68 ± 0.091.66 ± 0.080.251
Weight (Kg)#68.12 ± 10.7568.88 ± 11.0566.00 ± 9.800.262
BMI (Kg/m2)#24.11 ± 2.7124.19 ± 2.7423.91 ± 2.680.663
Oxygen saturation (%)90.0 (89.0, 93.0)91.0 (89.0, 93.0)90.0 (90.0, 92.0)0.816
SBP (mmHg)#126.9 ± 24.4128.7 ± 22.3122.1 ± 29.40.328
DBP (mmHg)#74.0 ± 13.573.9 ± 12.374.1 ± 16.80.960
Heart rate#76.8 ± 15.578.5 ± 15.072.1 ± 16.20.080
White blood cell7.20 (5.70, 11.09)7.05 (5.55, 10.96)7.88 (6.64, 11.33)0.471
Red blood cell4.77 (4.26, 5.31)4.75 (4.40, 5.39)4.78 (4.03, 5.22)0.365
Hemoglobin#151.1 ± 24.2153.2 ± 21.5145.0 ± 30.20.156
Glycosylated hemoglobin5.81 (5.47, 6.70)5.78 (5.46, 6.70)5.95 (5.59, 6.95)0.418
PT12.0 (11.5, 12.6)11.9 (11.4, 12.5)12.2 (11.9, 13.4)0.010
APTT27.6 (25.4, 31.2)27.5 (25.4, 30.8)30.7 (25.9, 32.8)0.072
ALT30.0 (19.0, 54.0)29.0 (19.0, 54.0)38.0 (17.0, 66.8)0.496
AST38.0 (22.0, 159.0)34.0 (21.0, 159.0)44.5 (22.3, 258.5)0.438
AST/ALT1.2 (0.8, 2.4)1.3 (0.9, 2.8)1.1 (0.7, 2.1)0.355
Urea nitrogen6.07 (4.98, 8.10)5.87 (4.97, 7.58)7.16 (5.99, 10.68)0.014
Creatinine84.0 (67.0, 94.0)82.0 (67.0, 93.0)84.5 (75.3, 114.5)0.242
Glomerular filtration rate (mL/min × 1.73 m2)#78.2 ± 25.280.6 ± 24.970.9 ± 25.10.109
Albumin37.8 (34.8, 40.6)38.0 (35.2, 40.7)36.6 (32.7, 38.3)0.085
Total cholesterol (mmol/L)#4.13 ± 1.124.13 ± 1.034.02 ± 1.370.699
Triglyceride1.42 (0.90, 2.14)1.59 (0.90, 2.18)1.32 (0.88, 1.87)0.418
TSH1.60 (0.86, 2.82)1.62 (0.85, 2.70)1.30 (0.88, 2.91)0.571

Sex, n (%)0.475
 Male63 (69.2)45 (67.2)18 (75.0)
 Female28 (30.8)22 (32.8)6 (25.0)

Aspirin resistance, n (%)0.660
 No42 (46.2)30 (44.8)12 (50.0)
 Yes49 (53.8)37 (55.2)12 (50.0)

Smoking history, n (%)0.039
 No52 (57.1)34 (50.7)18 (75.0)
 Yes39 (42.9)33 (49.3)6 (25.0)

Coronary heart disease type, n (%)0.932
 STEMI42 (46.2)31 (46.3)11 (45.8)
 NSTEMI12 (13.2)8 (11.9)4 (16.7)
 SAP15 (16.5)11 (16.4)4 (16.7)
 UA22 (24.2)17 (25.4)5 (20.8)

Hypertension, n (%)0.291
 No30 (33.0)20 (29.9)10 (41.7)
 Yes61 (66.7)47 (70.1)14 (58.3)

Diabetes, n (%)0.374
 No45 (49.5)35 (52.2)10 (41.7)
 Yes46 (50.5)32 (47.8)14 (58.3)

Stroke, n (%)0.473
 No59 (64.8)42 (62.7)17 (70.8)
 Yes32 (35.2)25 (37.3)7 (29.2)

Hyperlipidaemia, n (%)0.907
 No54 (59.3)40 (59.7)14 (58.3)
 Yes37 (40.7)27 (40.3)10 (41.7)

CYP2C192, n (%)0.120
 GG61 (67.0)45 (67.2)16 (66.7)
 GA24 (26.4)16 (23.9)8 (33.3)
 AA6 (6.6)6 (9.0)0 (0.0)

CYP2C193, n (%)0.527
 GG44 (48.4)34 (50.7)10 (41.7)
 GA26 (28.6)17 (25.4)9 (37.5)
 AA21 (23.0)16 (23.9)5 (20.8)

CYP2C1917, n (%)0.317
 GG57 (62.6)44 (65.7)13 (54.2)
 GA34 (37.4)23 (34.3)11 (45.8)

#mean ± sd, value, Han population vs. Tibetan population.